©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 28, 2015; 21(20): 6352-6360
Published online May 28, 2015. doi: 10.3748/wjg.v21.i20.6352
Published online May 28, 2015. doi: 10.3748/wjg.v21.i20.6352
Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis
Yu Jin, Yan Lin, Lian-Jie Lin, Chang-Qing Zheng, Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang 110021, Liaoning Province, China
Author contributions: Zheng CQ designed the study and wrote the protocol; Zheng CQ designed the study and helped with all correspondence related to this paper; Zheng CQ instructed on the whole study; Lin LJ performed experimental studies and acquired the data; Jin Y managed the literature searches; Lin LJ performed the statistical analysis; Lin Y put forward the definition of intellectual content; Jin Y wrote the first draft of the manuscript; all authors approved the final version of the manuscript.
Supported by Science and Technology Program of Liaoning Province, No. 2013225303.
Correspondence to: Chang-Qing Zheng, MD, Department of Gastroenterology, Shengjing Hospital of China Medical University, Huaxiang Branch, No. 9 Huaxiang Road, Tiexi District, Shenyang 110021, Liaoning Province, China. zhengchangqing88@163.com
Telephone: +86-24-9661526215 Fax: +86-24-9661526215
Received: August 26, 2014
Peer-review started: August 28, 2014
First decision: September 15, 2014
Revised: October 14, 2014
Accepted: December 1, 2014
Article in press: December 1, 2014
Published online: May 28, 2015
Processing time: 276 Days and 19.2 Hours
Peer-review started: August 28, 2014
First decision: September 15, 2014
Revised: October 14, 2014
Accepted: December 1, 2014
Article in press: December 1, 2014
Published online: May 28, 2015
Processing time: 276 Days and 19.2 Hours
Core Tip
Core tip: Studies have suggested that vedolizumab may be effective in reducing intestinal inflammation in patients with ulcerative colitis (UC). This meta-analysis including three randomized controlled trials showed that treatment with vedolizumab results in significantly higher clinical response and remission rates than placebo in patients with UC. Importantly, serious adverse events were not more common in vedolizumab-treated patients than control patients. This analysis supports the use of vedolizumab for the treatment of UC.